Genethon and WhiteLab Genomics Join Forces to Enhance Gene Therapy Through Artificial Intelligence
Summary
As part of this partnership, Genethon teams will use WhiteLab Genomics’ CatalystTM platform to develop new capsids, or vectors, which are essential components for gene therapy products. In this context, the use of artificial intelligence solutions stands out as a deciding factor to overcome these obstacles and produce optimized vectors that better target the relevant tissues, thus making it possible to inject smaller quantities of product while maximizing the effect of the therapy. Thanks to its Machine Learning algorithms, the WhiteLab Genomics platform will help researchers develop next-generation gene therapy vectors, with a view to enhancing their precision with regard to the tissues to be treated while reducing their immunogenic qualities. “France is a prime source of innovation in this field, and we look forward to helping research teams, in France and abroad, to make practical use of these extremely complex biological datasets, while also providing assistance to accelerate the development of optimized products.” Founded in 2019 by David Del Bourgo, Julien Cottineau and Lucia Cinque, WhiteLab Genomics is a French start-up specializing in artificial intelligence solutions dedicated to biotherapies, such as gene and cell therapies. Today, a product incorporating technologies developed thanks to Genethon’s pioneering research is available on the market in the United States, Europe and Japan to treat spinal muscular atrophy.